FGEN - FibroGen Inc Stock Price, Fair Value and News

0.98USD-0.09 (-8.41%)Market Closed

Market Summary

USD0.98-0.09

Market Closed

-8.41%

FGEN Stock Price

View Fullscreen

FGEN RSI Chart

FGEN Valuation

Market Cap

96.8M

Price/Earnings (Trailing)

-0.34

Price/Sales (Trailing)

0.66

EV/EBITDA

0.06

Price/Free Cashflow

-0.3

FGEN Price/Sales (Trailing)

FGEN Profitability

Operating Margin

87.24%

EBT Margin

-194.15%

Return on Equity

154.74%

Return on Assets

-67.11%

Free Cashflow Yield

-328.05%

FGEN Fundamentals

FGEN Revenue

Revenue (TTM)

147.8M

Rev. Growth (Yr)

-21.03%

Rev. Growth (Qtr)

-32.38%

FGEN Earnings

Earnings (TTM)

-284.2M

Earnings Growth (Yr)

15.03%

Earnings Growth (Qtr)

11.61%

Breaking Down FGEN Revenue

Last 7 days

-17.7%

Last 30 days

-58.5%

Last 90 days

10.3%

Trailing 12 Months

-93.7%

How does FGEN drawdown profile look like?

FGEN Financial Health

Current Ratio

1.52

FGEN Investor Care

Shares Dilution (1Y)

4.87%

Diluted EPS (TTM)

-2.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	116.1M	130.6M	155.0M	147.8M
2022	257.7M	263.1M	122.9M	140.7M
2021	191.1M	205.8M	220.6M	235.3M
2020	257.1M	108.4M	119.3M	176.3M
2019	204.9M	352.5M	356.7M	256.6M
2018	133.5M	147.2M	135.6M	213.0M
2017	184.3M	125.3M	135.8M	131.0M
2016	192.8M	161.5M	172.1M	183.2M
2015	136.0M	166.6M	172.5M	180.8M
2014	111.0M	119.9M	128.7M	137.6M
2013	0	0	0	102.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of FibroGen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 22, 2024	wettig thane	sold (taxes)	-2,017	2.58	-782	ceo
Mar 07, 2024	wettig thane	bought	95,470	1.9094	50,000	ceo
Mar 07, 2024	graham juan	sold (taxes)	-2,113	1.79	-1,181	chief financial officer
Mar 06, 2024	chung christine	acquired	-	-	781	svp, china operations
Mar 06, 2024	wettig thane	sold (taxes)	-8,480	1.87	-4,535	ceo
Mar 06, 2024	wettig thane	acquired	-	-	781	ceo
Mar 06, 2024	chung christine	sold (taxes)	-44,113	1.87	-23,590	svp, china operations
Mar 06, 2024	graham juan	acquired	-	-	781	chief financial officer
Mar 06, 2024	graham juan	sold (taxes)	-38,800	1.87	-20,749	chief financial officer
Feb 21, 2024	wettig thane	acquired	-	-	166,000	ceo

Which funds bought or sold FGEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.92	-	7,000	-%
Apr 19, 2024	Accel Wealth Management	new	-	103,294	103,294	0.04%
Apr 19, 2024	Cutler Group LLC / CA	reduced	-73.53	-1,000	2,000	-%
Apr 12, 2024	AdvisorNet Financial, Inc	new	-	4,700	4,700	-%
Apr 10, 2024	DAYMARK WEALTH PARTNERS, LLC	unchanged	-	21,809	35,015	-%
Apr 05, 2024	CWM, LLC	added	72.21	3,000	4,000	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	reduced	-0.32	190	8,198	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-47.06	-449	534	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-22.26	-1,575,460	6,243,230	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	11.25	50,154	401,604	-%

Are Funds Buying or Selling FGEN?

Are funds buying FGEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FGEN

No. of Funds

Unveiling FibroGen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	point72 asset management, l.p.	1.6%	1,600,000	SC 13G/A
Feb 14, 2024	armistice capital, llc	9.93%	9,764,000	SC 13G
Feb 13, 2024	vanguard group inc	7.16%	7,044,149	SC 13G/A
Feb 12, 2024	primecap management co/ca/	14.72%	14,471,928	SC 13G/A
Jan 26, 2024	blackrock inc.	7.3%	7,205,300	SC 13G/A
Jul 19, 2023	millennium management llc	4.7%	4,587,813	SC 13G
Feb 14, 2023	point72 asset management, l.p.	6.7%	6,281,645	SC 13G/A
Feb 09, 2023	primecap management co/ca/	14.79%	13,895,078	SC 13G/A
Feb 09, 2023	vanguard group inc	10.05%	9,444,069	SC 13G/A
Feb 08, 2023	first trust portfolios lp	3.17%	2,975,653	SC 13G/A

Recent SEC filings of FibroGen Inc

View All Filings

Date Filed	Form Type	Document
Mar 25, 2024	4	Insider Trading
Mar 11, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Feb 26, 2024	8-K	Current Report
Feb 26, 2024	10-K	Annual Report
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading

Peers (Alternatives to FibroGen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-12.04%	-45.12%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

FibroGen Inc News

Latest updates

FibroGen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-32.4%	27,138,000	40,134,000	44,319,000	36,161,000	34,366,500	15,735,000	29,806,000	60,827,000	16,543,000	155,973,000	24,364,000	44,681,250	64,998,500	44,032,000	42,888,000	24,401,000	7,974,000	33,174,000	191,566,000	23,863,000	108,054,500
Cost Of Revenue	27.4%	5,406,500	4,243,000	5,708,000	3,491,000	4,925,000	4,308,000	6,809,000	4,238,000	3,125,500	3,266,000	3,078,000	3,401,000	-	2,207,000	-	-	-	-	-	-	-
Costs and Expenses	-21.5%	81,332,500	103,616,000	132,367,000	112,252,000	100,518,000	109,392,000	108,030,000	123,820,000	151,784,500	104,999,000	158,199,000	108,856,000	-	11,702,000	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	158,199,000	108,856,000	122,997,000	11,702,000	128,025,000	105,475,000	108,410,000	86,028,000	78,747,000	72,706,000	88,135,000
S&GA Expenses	-5.3%	24,223,000	25,573,000	31,181,000	34,275,000	33,965,000	29,902,000	30,258,000	30,564,000	34,739,000	25,853,000	32,554,000	30,779,000	42,249,000	-48,981,000	63,535,000	49,603,000	50,707,000	35,823,000	26,739,000	22,210,000	17,851,000
R&D Expenses	-15.5%	51,703,000	61,194,000	95,478,000	74,486,000	61,628,000	75,182,000	70,963,000	89,018,000	113,920,000	75,880,000	122,567,000	74,676,000	78,132,000	58,476,000	61,414,000	54,902,000	56,798,000	49,963,000	52,008,000	50,496,000	70,284,000
EBITDA Margin	0.0%	-1.77	-1.77	-2.35	-2.54	-2.01	-2.87	-0.80	-1.06	-1.19	-0.92	-1.06	-0.88	-	-	-	-	-	-	-	-	-
Interest Expenses	0.9%	5,068,500	5,022,000	3,069,000	2,372,000	1,118,500	84,000	141,000	97,000	110,000	109,000	355,000	501,000	538,000	580,000	651,000	633,000	667,500	702,000	736,000	770,000	2,733,500
Income Taxes	-4.8%	80,000	84,000	-235,000	74,000	108,000	114,000	23,000	113,000	111,000	106,000	-3,000	134,000	170,000	215,000	169,000	-194,000	72,000	76,000	205,000	-25,000	5,500
Earnings Before Taxes	11.6%	-56,767,000	-64,208,000	-88,465,000	-77,427,000	-66,347,500	-91,943,000	-73,166,000	-63,412,000	-134,310,000	49,562,000	-134,553,000	-71,381,000	-58,275,000	33,232,000	-85,144,000	-78,542,000	-98,051,000	-49,363,000	116,208,000	-45,436,000	20,958,500
EBT Margin	-1.5%	-1.94	-1.91	-2.48	-2.66	-2.10	-2.95	-0.84	-1.10	-1.24	-0.97	-1.12	-0.95	-	-	-	-	-	-	-	-	-
Net Income	11.6%	-56,232,000	-63,615,000	-87,680,000	-76,705,000	-66,175,000	-91,650,000	-72,624,000	-63,205,000	-134,078,000	49,798,000	-133,988,000	-71,755,000	-58,634,000	33,004,000	-85,313,000	-78,348,000	-98,123,000	-49,439,000	116,003,000	-45,411,000	20,953,000
Net Income Margin	-1.3%	-1.92	-1.90	-2.47	-2.65	-2.09	-2.94	-0.84	-1.09	-1.23	-0.97	-1.12	-0.96	-	-	-	-	-	-	-	-	-
Free Cashflow	78.2%	-18,572,000	-85,222,000	-111,564,000	-102,182,000	-52,846,000	-52,745,000	-33,969,000	-10,114,000	-56,356,000	42,680,000	-28,240,000	-45,502,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-8.0%	424	460	515	539	610	609	687	746	774	851	809	787	827	812	808	824	857	894	915	812	881
Current Assets	-8.9%	332	364	411	431	493	474	521	524	474	573	564	622	755	737	727	736	702	786	806	579	690
Cash Equivalents	-6.0%	114	121	153	189	156	156	168	186	171	275	353	434	678	532	429	122	126	197	75.00	82.00	89.00
Inventory	2.1%	42.00	41.00	41.00	42.00	40.00	40.00	41.00	43.00	31.00	29.00	25.00	21.00	17.00	12.00	9.00	8.00	7.00	5.00	2.00	-	-
Net PPE	-9.6%	13.00	15.00	17.00	19.00	21.00	22.00	25.00	27.00	28.00	29.00	31.00	31.00	34.00	36.00	37.00	40.00	43.00	43.00	45.00	46.00	127
Liabilities	1.8%	586	576	575	567	612	563	563	568	545	505	529	397	385	341	393	347	322	280	267	304	352
Current Liabilities	3.9%	218	209	194	255	274	252	240	255	225	209	233	167	163	118	78.00	66.00	103	87.00	83.00	94.00	89.00
Shareholder's Equity	-Infinity%	-183	-	-	-	-1.48	46.00	124	178	229	345	280	390	441	471	415	478	535	614	648	508	528
Retained Earnings	-3.1%	-1,841	-1,785	-1,722	-1,634	-1,557	-1,491	-1,399	-1,327	-1,264	-1,129	-1,179	-1,045	-974	-915	-948	-863	-784	-686	-637	-753	-715
Additional Paid-In Capital	0.6%	1,644	1,634	1,625	1,589	1,541	1,524	1,510	1,491	1,476	1,459	1,444	1,420	1,400	1,370	1,345	1,319	1,301	1,280	1,266	1,242	1,226
Shares Outstanding	0.4%	99.00	98.00	98.00	97.00	94.00	93.00	93.00	93.00	92.00	93.00	92.00	92.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	20.00	20.00	20.00	20.00	20.00	20.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00
Float	-	-	-	262	-	-	-	975	-	-	-	1,447	-	-	-	2,128	-	-	-	2,464	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	78.3%	-18,321	-84,538	-110,571	-101,591	-52,513	-51,880	-33,064	-8,476	-54,960	44,255	-26,543	-44,984	-7,228	-1,349	149,665	-59,486	-45,050	-27,483	-28,652	22,480	-17,465
Share Based Compensation	-1.9%	9,296	9,476	15,883	16,112	16,224	15,567	16,658	17,152	17,072	15,704	19,001	19,384	20,269	17,891	17,644	16,916	17,402	14,793	17,642	16,430	13,710
Cashflow From Investing	-81.1%	10,242	54,218	-14,285	103,482	1,093	44,783	17,305	25,935	-50,567	-122,153	-57,533	-196,719	143,768	98,855	153,855	56,009	-25,033	152,768	18,770	-26,487	-462,856
Cashflow From Financing	-1018.2%	-246	-22.00	91,532	31,485	48,674	-1,092	2,087	-2,893	-31.00	-833	2,381	-2,080	5,659	4,225	4,649	-1,190	-284	-3,236	2,754	-3,534	2,818

FGEN Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 147,752	$ 140,734	$ 235,309
Operating costs and expenses:
Cost of goods sold	$ 18,848	$ 20,280	$ 12,871
Cost, Product and Service [Extensible List]	Product Revenue, Net [Member]	Product Revenue, Net [Member]	Product Revenue, Net [Member]
Research and development	$ 282,861	$ 296,791	$ 387,043
Selling, general and administrative	115,252	124,688	123,925
Restructuring charge	12,606	0	0
Total operating costs and expenses	429,567	441,759	523,839
Loss from operations	(281,815)	(301,025)	(288,530)
Interest and other, net
Interest expense	(15,532)	(1,440)	(1,075)
Interest income and other income (expenses), net	10,480	7,596	(1,078)
Total interest and other, net	(5,052)	6,156	(2,153)
Loss before income taxes	(286,867)	(294,869)	(290,683)
Provision for income taxes	3	358	347
Share of Net Income	2,638	1,573	1,007
Net loss	$ (284,232)	$ (293,654)	$ (290,023)
Net loss per share - basic	$ (2.92)	$ (3.14)	$ (3.14)
Net loss per share - diluted	$ (2.92)	$ (3.14)	$ (3.14)
Weighted average number of common shares used to calculate net loss per share - basic and diluted
Basic	97,303	93,582	92,349
Diluted	97,303	93,582	92,349
License Revenue [Member]
Revenue:
Total revenue	$ 9,649	$ 22,590	$ 116,434
Development and Other Revenue [Member]
Revenue:
Total revenue	18,401	24,189	70,275
Product Revenue, Net [Member]
Revenue:
Total revenue	100,949	82,869	47,638
Drug Product Revenue, Net [Member]
Revenue:
Total revenue	$ 18,753	$ 11,086	$ 962

FGEN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 113,688	$ 155,700
Short-term investments	121,898	266,308
Accounts receivable, net ($6,079 and $12,088 from related parties)	12,553	16,299
Inventories	41,565	40,436
Prepaid expenses and other current assets	41,855	14,083
Total current assets	331,559	492,826
Restricted time deposits	1,658	2,072
Long-term investments	0	4,348
Property and equipment, net	13,126	20,605
Equity method investment in unconsolidated variable interest entity	5,290	5,061
Operating lease right-of-use assets	68,093	79,893
Other assets	3,803	5,282
Total assets	423,529	610,087
Current liabilities:
Accounts payable	17,960	30,758
Accrued and other current liabilities ($39,814 and $63,886 to a related party)	172,891	219,773
Deferred revenue ($7,220 and $9,259 to related parties)	12,740	12,739
Operating lease liabilities, current	14,077	10,292
Total current liabilities	217,668	273,562
Product development obligations	17,763	16,917
Deferred revenue, net of current ($9,705 and $31,044 to a related party)	157,555	185,722
Operating lease liabilities, non-current	66,537	79,593
Senior secured term loan facilities, non-current	71,934	0
Liability related to sale of future revenues, non-current	51,413	49,333
Other long-term liabilities ($656 and $0 to a related party)	2,858	6,440
Total liabilities	585,728	611,567
Commitments and Contingencies (Note 12)
Redeemable non-controlling interests	21,480	0
Stockholders' deficit:
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022
Common stock, $0.01 par value; 225,000 shares authorized at December 31, 2023 and 2022; 98,770 and 94,166 shares issued and outstanding at December 31, 2023 and 2022	988	942
Additional paid-in capital	1,643,641	1,541,019
Accumulated other comprehensive loss	(6,875)	(5,720)
Accumulated deficit	(1,841,920)	(1,557,688)
Total stockholders' deficit attributable to FibroGen	(204,166)	(21,447)
Nonredeemable non-controlling interests	20,487	19,967
Total deficit	(183,679)	(1,480)
Total liabilities, redeemable non-controlling interests and deficit	$ 423,529	$ 610,087

About FibroGen Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

WEBSITE	fibrogen.com
INDUSTRY	Biotechnology
EMPLOYEES	592

FibroGen Inc Frequently Asked Questions

What is the ticker symbol for FibroGen Inc? What does FGEN stand for in stocks?

FGEN is the stock ticker symbol of FibroGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of FibroGen Inc (FGEN)?

As of Tue Apr 23 2024, market cap of FibroGen Inc is 105.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FGEN stock?

You can check FGEN's fair value in chart for subscribers.

What is the fair value of FGEN stock?

You can check FGEN's fair value in chart for subscribers. The fair value of FibroGen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of FibroGen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is FibroGen Inc a good stock to buy?

The fair value guage provides a quick view whether FGEN is over valued or under valued. Whether FibroGen Inc is cheap or expensive depends on the assumptions which impact FibroGen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FGEN.

What is FibroGen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, FGEN's PE ratio (Price to Earnings) is -0.37 and Price to Sales (PS) ratio is 0.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FGEN PE ratio will change depending on the future growth rate expectations of investors.